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follow-up in subsequent years following a cardiovascular event. First-year costs of
the cardiovascular events considered were: myocardial infarction (US$5,026); an-
gina(US$2378); congestive heart failure (US$3314); stroke (US$5006) and peripheral
vascular disease (US$2508). The cost of laser intervention was US$4248, while the
cost of a cataract operation was US$2916. CONCLUSIONS: Costs for treating diabe-
tes-related complications are an important driver of economic burden for DM.
Costs presented in this study provide useful inputs for further economic evalua-
tions of DM treatments in Mexico.
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OBJECTIVES: Diabetes mellitus (DM) represents a challenging problem to health-
care systems globally as it requires a high level of expenditure. In Algeria, nearly
US$264 million was spent on DM in 2010; this is expected to rise to US$461 million
by 2030. The aim of this study was to collect 2011 direct medical costs of the
management and treatment of DM-related complications from the Algerian Social
Insurance perspective.METHODS:A structured literature searchwas conducted to
search for the published costs of interest but no relevant publications were iden-
tified. Consequently, IMS collected the required costs from official sources identi-
fied using its local resources. Six groups of costs were created basedmainly on type
of complications: management costs, cardiovascular complications, renal compli-
cations, acute events, eye-disease and neuropathy/foot ulcers which were pre-
sented as first-year costs and costs in subsequent years following an event in 2011
US-dollars (1 US$72.868 AD). RESULTS: The highest first year costs were observed
in the renal complications group; renal transplantation (US$28,422), continuous
ambulatory peritoneal dialysis (US$3,901) and haemodialysis (US$3,742). High an-
nual costs were also associated with the treatment of cardiovascular complica-
tions, ranging from US$865 for first-year treatment of myocardial infarction to
US$132 for first-year treatment of peripheral vascular disease. Other first-year
costs of treating cardiovascular events were: stroke (US$282), congestive heart fail-
ure (US$244), and angina (US$395). The cost of an amputation procedure was
US$533, excluding the cost of prosthesis (US$618), with a follow-up cost of US$22.
The cost of a laser eye procedure was US$48, while the cost of a cataract operation
was US$123. CONCLUSIONS: The study identified the Social Insurance costs re-
lated to treating DM complications which may add to the financial burden on the
Algerian health care system. Data from this study may be used further to evaluate
the economic impact of DM-related treatments in Algeria.
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OBJECTIVES: Health care systems in many countries are facing a significant finan-
cial burden due to the costs incurred by treating Diabetes mellitus (DM). In Brazil,
expenditure on DM care in 2010 was estimated at US$4.3million and is expected to
rise to nearly US$7.2 million by 2030. This study aims to collect up-to-date direct
medical costs of managing and treating DM-related complications from the Brazil-
ian health care system perspective.METHODS:Most costs were obtained from the
Brazilian Ministry of Health and published studies identified through a structured
literature search. Pre-2011 costs were inflated using the Consumer Price Index.
Costs were categorised in six groups: management costs, cardiovascular compli-
cations, renal complications, acute events, eye-disease and neuropathy/foot ul-
cers. Costs were expressed in 2011 US-dollars in accordance with the average an-
nual exchange rate (1 US$1.669 BRL) and were reported as per event costs in the
first-year of the event and in subsequent years following the event. RESULTS:
First-year haemodialysis and renal transplantation costs were the highest costs
observed overall at US$14,855 and US$14,051, respectively. The highest first-year
cost of treating cardiovascular complications was that for myocardial infarction
(US$4752). Other first-year costs of treating cardiovascular complications were:
congestive heart failure (US$2,852), stroke (US$1812) and angina (US$532). The cost
of an amputation procedure was US$3771 without the cost of prosthesis (US$1584).
The cost of a laser eye operation was US$2064 and the cataract operation cost was
US$507. CONCLUSIONS: DM-related complications impose significant costs on the
Brazilian health care budget which highlights the importance of conducting eco-
nomic evaluations to assess the impact of DM-related treatments on treatment
costs and health outcomes. Costs from this study can be used to conduct such
economic evaluations which provide valuable information to decision makers in
the assessment of DM-related treatments.
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OBJECTIVES: In Kenya, diabetes prevalence is comparable toWestern countries. In
Sub-Saharan countries, the emphasis must be on prevention because theWestern
model of emphasizing treatment is unaffordable and unachievable. This study is a
cost benefit analysis (CBA) of a diabetes prevention program in rural Kenya.
METHODS: Convenience sample of adult residents from a rural county in Kenya
(Kiambu)were randomized to one of twoWTP techniques, StructuredHaggling (SH)
and Payment Card (PC). Program benefits (WTP) were collected via face-to-face
interviews using the ex-ante approach. Program costs were estimated based on
World Health Organization program cost estimation guidelines for low income
countries in Africa, and program costs tabulated in the literature (eg Haddix et al
2006), supplemented expert opinion: diabetes educators at the Kenya Diabetes
Management and Information Centre. RESULTS:WTP data was collected from 158
rural residents (70% male, 2.5% diabetic,11% own a vehicle and mean monthly
expenditures of Ksh10,933 (US2011$ 127.12). Mean annual WTP for the prevention
program was Ksh628.75 (US2011$7.30) for PC and Ksh683.97 (US2011$7.95) for SH
per respondent per year, p0.516. Mean annual cost for providing the program to
rural residents (assuming 100 clients/week) was Ksh1,228 (US2011$14). Therefore,
program cost exceeded the benefit resulting in a negative net social benefit (NSB).
CONCLUSIONS: Based onWTP (benefit) data, residents valued the diabetes preven-
tion program in rural Kenya. From a societal perspective, however, the costs for
implementing the program outweighed the benefits. The evaluated program is a
stand-alone project. Policy makers may consider a number of options that can
reduce the operating costs of the program including, implementation of the pro-
gram as part of established diabetes clinics, or administering the services to al-
ready gathered groups such as at religious functions: such an approachmay result
in a positive NSB.
PDB50
LONG-TERM CLINICAL AND ECONOMIC BENEFIT ASSOCIATED WITH
LIRAGLUTIDE VERSUS SITAGLIPTIN THERAPY WHEN ADDED TO METFORMIN
IN THE TREATMENT OF TYPE 2 DIABETES: A CORE DIABETES MODEL STUDY
Lee WC1, Samyshkin Y2, Langer J3, Palmer JL4
1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health Consulting Group, London,
UK, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4IMS Health Consulting Group, Allschwil, Basel-
Land, Switzerland
OBJECTIVES: A recent randomized, open-label, parallel group trial showed that
liraglutide is superior to sitagliptin for reduction of HbA1c. Although these findings
support the use of liraglutide as an effective GLP-1 agent to add to metformin, the
value of liraglutide needs to be quantified in the framework of a cost-effectiveness
(CE) analysis in a US setting. This current study sets out to assess the long-term CE
outcomes of liraglutide vs. sitagliptin based on treatment effects data from the
52-week trial. METHODS: The IMS CORE Diabetes Model, a non-product-specific,
validated computer simulation model that projects the long-term outcomes re-
lated to interventions for type 2 diabetes, is used for simulation over 35 years.
Patients were simulated on one of the 3 treatment options: liraglutide 1.2 mg daily,
1.8mg daily, or sitagliptin 100mg daily, each used as add-on therapy tometformin.
Incremental cost-effectiveness ratios (ICER) were generated for liraglutide 1.2 mg
versus sitagliptin and liraglutide 1.8 mg versus sitagliptin. Transition probabilities,
health state utility values and complication costs were obtained from published
sources. All outcomes were discounted at 3% per annum, and the analysis was
conducted from the perspective of a third-party payer in the US. Sensitivity anal-
yses were performed to test robustness of the base case scenario. RESULTS: For
liraglutide 1.8 mg versus sitagliptin, the ICER was $37,234 per QALY gained, while
for liraglutide 1.2mg versus sitagliptin, the ICERwas $25,742 perQALY gained. In all
sensitivity analyses including setting the HbA1c reduction to its 95% lower limit,
the ICERs remained below USD 50,000/QALY, a commonly accepted threshold in
the United States, except for the shortest time horizon of 10 years. CONCLUSIONS:
The availability of liraglutide 1.2mg and 1.8mgwith improved efficacy profiles over
sitagliptin could improve patient care, while being cost-effective treatment options
as add-on to metformin.
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OBJECTIVES: Although, safety and efficacy of exenatide BID (exenatide) and lira-
glutide for treating type 2 diabetes (T2D) has been demonstrated in trials, their
comparative economic benefits are unknown. This study examined cost offsets
and medication adherence with use of exenatide versus liraglutide in managed
care population. METHODS: A retrospective cohort analysis was conducted using
the LifeLink database, comprising adult patients with T2D who initiated exenatide
(n2383) or liraglutide (n1535) between January 1, 2010 and June 30, 2010 andwith
6months pre- andpost-index continuous eligibility. Patientswere propensity score
matched to control for on baseline differences. Medication adherence was mea-
sured using the proportion of days covered (PDC). The paired t-test andMcNemar’s
test were used to compare outcomes. RESULTS:Matched exenatide and liraglutide
cohorts (n1347 pairs) had comparable age (54 vs. 53 years), gender (55% vs. 57%
female), and comorbidities (86% vs. 86%). In the 6-month follow-up, exenatide and
liraglutide patients had similar mean total costs ($6688 vs. $7346). Significant cost
savings were observed in mean total pharmacy costs ($2925 vs. $3272, P 0.001).
There were no significant differences in mean total outpatient ($2541 vs. $3050) or
inpatient ($1222 vs. $1025) costs. Among patientswho initiated liraglutide, those on
1.8mgdoses (n638) had significantly highermean total costs than those on 1.2mg
doses (n438) ($8046 vs. $6737, P 0.043) due to higher mean total pharmacy costs
in the 1.8 mg cohort ($4017 vs. $3295, P 0.001); 35% higher mean drug cost for
liraglutide claims in the 1.8 mg cohort largely accounted for this difference ($1876
vs. $1390, P 0.001). There was no significant difference in medication adherence
between groups (mean PDC: exenatide 56% vs. liraglutide 57%). CONCLUSIONS:
Patients initiating exenatide versus liraglutide for the management of T2D had
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